Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Bayer    BAYN   DE000BAY0017

BAYER (BAYN)
Mes dernières consult.
Most popular
Real-time Quote. Real-time Tradegate - 10/17 11:50:33 am
118.176 EUR   -1.19%
10:18a BAYER : foundations bring tech pioneers physicians and social entrep..
10/14DJBAYER : Unloads Assets to Aid Deal -- WSJ
10/13 BASF CEO says to look at more seed M&A after Bayer deal
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Bayer : Brazil agency says Bayer-Monsanto tie-up can hurt competition, urges conditions

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/04/2017 | 08:41pm CEST
FILE PHOTO: Monsanto logo is displayed on a screen where the stock is traded on the floor of the NYSE

A unit of Brazil's competition regulator Cade has said Bayer AG's (>> Bayer) proposed takeover of Monsanto Co. (>> Monsanto) could be detrimental to competition and urged conditions for Brazilian approval of the corporate tie-up, a document released on the agency's website shows.

A unit of Brazil's competition regulator Cade has said Bayer AG's (>> Bayer) proposed takeover of Monsanto Co. (>> Monsanto) could be detrimental to competition and urged conditions for Brazilian approval of the corporate tie-up, a document released on the agency's website shows.

The Bayer-Monsanto transaction, announced in September 2016, would create the world's largest integrated pesticides and seeds company.

The Cade unit said that anticipated merger-related efficiencies were insufficient to mitigate its competition concerns, according to the document dated Oct. 3.

It recommended what it termed as "structural solutions" as a condition for final approval the deal, which will be in the hands of Cade's seven-member tribunal.

Cade has 330 days to make a final decision since it began its review of the deal on April 24, a spokesman for the agency said. However, he added it may announce a ruling as early as Dec. 20.

The Cade unit said solutions included creating or strengthening another player to compete in the markets for soy and cotton seeds and in the sphere of biotech development.

But the unit has not engaged in an in-depth discussion with Bayer and Monsanto related to its suggested "remedies," the document said.

In an emailed statement to Reuters, Bayer said the unit's opinion is non-binding and does not mean the transaction will be blocked.

Hugh Grant, Monsanto's chief executive officer, said concerns expressed by Brazil's regulator are a normal step in the review process.

Brazil is Monsanto's biggest market outside of the United States.

In its second-quarter results, Bayer said sales of its crop science division tumbled more than 15 percent primarily because of its business in Brazil, an indication of the country's weight as a market for seed technology, insecticides and herbicides.

Deal opponents have asked Cade to block it or force divestments including Monsanto's Intacta RR2 IPRO soy seed technology and Bayer's glufosinate ammonium herbicides.

Last week, Monsanto's chief executive officer for South America, Rodrigo Santos, told Reuters the company was set on keeping rights to Intacta.

Cotton farmers against the transaction assert the merged company would control 14 out of 15 genetically modified cotton seed technologies available in Brazil.

If Cade orders asset disposals from the companies, authorities must see to it that the buyer is a relevant player in the biotech, seed production and crop defence segments, said attorney Rachel Mendonça, a partner at Mendonça e Nogueira Advogados.

Her law firm is representing three industry groups opposing the deal.

(Reporting by Ana Mano; editing by Alexander Smith and W Simon)

By Ana Mano

Stocks treated in this article : Monsanto, Bayer
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BAYER
10:18a BAYER : foundations bring tech pioneers physicians and social entrepreneurs to t..
10/16 BAYER : Health and Human Services Department (HHS); Food and Drug Administration..
10/14DJBAYER : Unloads Assets to Aid Deal -- WSJ
10/13 BASF CEO says to look at more seed M&A after Bayer deal
10/13 Bayer sells units to be able to complete Monsanto takeover
10/13 BAYER : foundations bring tech pioneers, physicians and social entrepreneurs to ..
10/13DJBASF to Buy Large Parts of Bayer's Seed and Non-Selective Herbicide Businesse..
10/13 BAYER AKTIENGESELLSCHAFT : Release according to Article 26, Section 1 of the WpH..
10/13DJBASF : Signs Agreement To Acquire Significant Parts Of Bayer's Seed And Non-Sele..
10/13 BAYER : signs agreement to sell selected Crop Science businesses to BASF for EUR..
More news
News from SeekingAlpha
10/16 BASF (BASFY) To Acquire Significant Parts Of Bayer's (BAYZF) Seed And Non-Sel..
10/14 BASF Buys Bayer's Crop Science Assets At A Fair Price
10/13 WALL STREET BREAKFAST : The Beat Goes On For Global Stocks As Records Continue T..
10/13 Bayer to sell seed, herbicide assets to BASF for $7B, subject to Monsanto dea..
10/12 UK's NHS to routinely offer Bayer's cancer med Stivarga
Financials (€)
Sales 2017 48 368 M
EBIT 2017 9 231 M
Net income 2017 5 396 M
Debt 2017 12 235 M
Yield 2017 2,32%
P/E ratio 2017 19,67
P/E ratio 2018 17,76
EV / Sales 2017 2,30x
EV / Sales 2018 2,19x
Capitalization 98 903 M
Chart BAYER
Duration : Period :
Bayer Technical Analysis Chart | BAYN | DE000BAY0017 | 4-Traders
Technical analysis trends BAYER
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 121 €
Spread / Average Target 1,1%
EPS Revisions
Managers
NameTitle
Werner Baumann Chairman-Management Board
Werner Wenning Chairman-Supervisory Board
Johannes M. Dietsch Chief Financial Officer
Katharina Jansen Head-Science & Research
Hartmut Klusik Head-Human Resources, Technology & Sustainability
Sector and Competitors
1st jan.Capitalization (M$)
BAYER19.19%116 409
JOHNSON & JOHNSON18.42%365 346
NOVARTIS13.23%226 956
ROCHE HOLDING LTD.5.20%215 359
PFIZER11.88%214 265
MERCK AND COMPANY7.68%172 751